Therapy implications of the role of interleukin-2 in cancer

References

• Grimm EA, Mazumder A, Zhang HZ, et al. Lymphokine-activated killer cell phenomenon. J Exp Med. 1982;155:1823–1841.
   PubMed Web of Science ®Google Scholar
• Lissoni P, Barni S, Rovelli F, et al. Lower survival in metastatic cancer patients with reduced interleukin-2 blood concentrations. Oncology. 1991;48:125–127.
   PubMed Web of Science ®Google Scholar
• Whittington R, Faulds D. Interleukin-2. Drugs. 1993;46:446–483.
   PubMed Web of Science ®Google Scholar
• Kunutso KL, Disis ML, Salazar LG. CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Ther. 2007;556:2471–2485.
   Google Scholar
• Foon KA. Biological response modifiers: the new immunotherapy. Cancer Res. 1989;49:1621–1627.
   PubMed Web of Science ®Google Scholar
• Chouaib S, Fradelizi D. The mechanism of inhibition of human IL-2 production. J Immunol. 1982;129:2463–2468.
   PubMed Web of Science ®Google Scholar
• Wojtowicz-Praga S. Reversal of tumor induced immunosuppression: a new approach to cancer therapy. J Immunother. 1997;20:165–177.
   PubMed Web of Science ®Google Scholar
• Thornton A, Shevach EM. Suppressor effector function of CD4+CD25+immunoregulatory T cells is a non-specific antigen. J Immunol. 2000;164:183–190.
   PubMed Web of Science ®Google Scholar
• Shevach EM. CD4+CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol. 2002;2:389–400.
   PubMed Web of Science ®Google Scholar
• Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol. 2006;6:295–307.
   PubMed Web of Science ®Google Scholar
• Carbone DP, Gandara DR, Antonia SJ, et al. Non-small cell lung cancer. Role of the immune system and potential for immunotherapy. J ThoracOncol. 2015;10:974–984.
   PubMed Web of Science ®Google Scholar
• Prochazkova J, Pokorna K, Holan V. IL-12 inhibits the TGF-beta- T cell development programs and skews the TGF-beta-induced differentiation into a Th1-like direction. Immunobiology. 2012;217:74–82.
   PubMed Web of Science ®Google Scholar
• Pappu R, Ramirez-Carrozzi V, Sambandam A. The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases. Immunology. 2011;134:8–16.
   PubMed Web of Science ®Google Scholar
• Attridge K, Wang CJ, Wardzinski L, et al. IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood. 2012;119:4656–4664.
   PubMed Web of Science ®Google Scholar
• Gallimore AM, Simon AK. Positive and negative influences of regulatory T cells on tumour immunity. Oncogene. 2008;27:5886–5893.
   PubMed Web of Science ®Google Scholar
• Riley V. Psychoneuroendocrine influences on immunocompetence and neoplasia. Science. 1981;212:1100–1109.
   PubMed Web of Science ®Google Scholar
• Trosko JE, Ruch RJ. Cell-cell communication in carcinogenesis. Front Biosci. 1998;3:208–236.
   PubMedGoogle Scholar
• Kim R, Emi M, Tanabe K, et al. The role of Fas ligand and transforming growth factor-beta in tumor progression. Cancer. 2004;100:2281–2291.
   PubMed Web of Science ®Google Scholar
• Shibakita M, Tachibana M, Dhar DK, et al. Prognostic significance of FAS and FAS ligand expressions in human esophageal cancer. Clin Cancer Res. 1999;5:25464–25469.
   Web of Science ®Google Scholar
• Brzezinski A. Melatonin in humans. N Egl J Med. 1997;336:186–195.
   PubMed Web of Science ®Google Scholar
• Mormont MC, Levi F. Circadian system alterations during cancer processes: a review. Int J Cancer. 1997;70:241–247.
   PubMed Web of Science ®Google Scholar
• Fumagalli L, Lissoni P, Di Felice G, et al. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Br J Cancer. 1999;80:407–411.
   PubMed Web of Science ®Google Scholar
• Lissoni P, Fumagalli L, Rovelli F, et al. In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients. Br J Cancer. 1998;77:1957–1960.
   PubMed Web of Science ®Google Scholar
• Brivio F, Fumagalli L, Parolini D, et al. T-helper/T-regulator lymphocyte ratio as a new immunobiological index to quantify the anticancer immune status in cancer patients. In Vivo. 2008;22:647–650.
   PubMed Web of Science ®Google Scholar
• Lissoni P, Brivio F, Fumagalli L, et al. Effects of the conventional antitumor therapies: surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients. Anticancer Res. 2009;29:1847–1852.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA. The immunotherapy and gene therapy of cancer. J ClinOncol. 1992;10:181–191.
   Web of Science ®Google Scholar
• West WH. Continuous infusion recombinant interleukin-2 (r-IL-2) in adoptive cellular therapy of renal carcinoma and other malignancies. Cancer Treat Rev. 1989;16:83–89.
   PubMed Web of Science ®Google Scholar
• Atzpodien J, Kirchner H. Cancer, cytokines and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr. 1990;68:1–11.
   PubMedGoogle Scholar
• Lissoni P. Prognostic markers in interleukin-2 therapy. Cancer Biother Radiopharm Col. 1996;11:285–287.
   PubMed Web of Science ®Google Scholar
• Recchia F, Saggio G, Nuzzo A, et al. Multicentric phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small cell lung cancer. J Immunother. 2006;29:87–94.
   PubMed Web of Science ®Google Scholar
• Lissoni P. The pineal gland as a central regulator of cytokine network. Neuroendocrinol Lett. 1999;20:343–349.
   PubMedGoogle Scholar
• Antony MH. Psychoneuroimmunology of cancer. Brain BehavImmunol. 2003;17:84–91.
   Web of Science ®Google Scholar
• Lewis JW, Shavit Y, Terman GW, et al. Apparent involvement of opioid peptides in stress-induced enhancement of tumor growth. Peptides. 1983;4:635–638.
   PubMed Web of Science ®Google Scholar
• Sze SF, Ng TB, Liu WK. Antiproliferative effect of pineal indoles on cultured tumor cell lines. J Pineal Res. 1993;14:27–33.
   PubMed Web of Science ®Google Scholar
• Maestroni GJM. The immune neuroendocrine role of melatonin. J Pineal Res. 1993;14:1–10.
   PubMed Web of Science ®Google Scholar
• Lissoni P, Brivio F, Fumagalli L, et al. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res. 2008;28:1377–1382.
   PubMed Web of Science ®Google Scholar
• West EE, Jin HT, Rasheed AU, et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest. 2013;123:2604–2615.
   PubMed Web of Science ®Google Scholar
• King IL, Segal BM. Cutting edge: IL-12 induces CD4+CD25- T. Cell activation in the presence of T regulatory cells. J Immunol. 2005;175:641–645.
   PubMed Web of Science ®Google Scholar
• Lissoni P, Malugani F, Bordin V, et al. A new neuro immunotherapeutic strategy of subcutaneous low-dose interleukin-2 plus the long-acting opioid antagonist naltrexone in metastatic cancer patients progressing on IL-2 alone. Neuroendocrinol Lett. 2002;23:255–258.
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Interleukin-15 in the treatment of cancer. Exp Rev Clin Immunol. 2014;10:1689–1701.
   PubMed Web of Science ®Google Scholar
• Lissoni P, Brivio F, Fumagalli L, et al. Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pre-treatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy. Vivo. 2005;19:1077–1080.
   PubMed Web of Science ®Google Scholar
• Ehrke MJ, Mihich E, Berd D, et al. Effects of anticancer. Drugs on the immune system in humans. Semin Oncol. 1989;16:230–239.
   PubMed Web of Science ®Google Scholar
• Conti A, Maestroni GJM. The clinical neuroimmunotherapeutic role of melatonin in oncology. J Pineal Res. 1995;19:103–110.
   PubMed Web of Science ®Google Scholar
• Nagarkatti P, Pandey R, Rieder SA, et al. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009;1:1333–1349.
   PubMed Web of Science ®Google Scholar